First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
Saskia GlasauerDoris AltmannBarbara HauerBonita BrodhunWalter HaasNita PerumalPublished in: PloS one (2019)
DR patterns observed in Germany, particularly for MDR-TB were more complex than expected, highlighting the fact that detailed drug-testing results are crucial before incorporating HRZES drugs in MDR-TB treatment. Furthermore, the relatively high rate of H-resistance in Germany provides strong rationale against the use of only H-based preventive therapy for LTBI.